Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus FAMCICLOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus FAMCICLOVIR.
ADEFOVIR DIPIVOXIL vs FAMCICLOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Famciclovir is a prodrug of penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thus inhibiting viral DNA replication. It has activity against herpes simplex virus (HSV-1, HSV-2), varicella-zoster virus (VZV), and Epstein-Barr virus (EBV).
10 mg orally once daily on an empty stomach.
500 mg orally three times daily for 7 days for herpes zoster; 125 mg twice daily for 5 days for recurrent genital herpes; 250 mg three times daily for 7 days for first-episode genital herpes; 500 mg twice daily for 7 days for recurrent herpes labialis.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Clinical Note
moderateFamciclovir + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Famciclovir."
Clinical Note
moderateTerminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal half-life of penciclovir is 2-3 hours in healthy adults, prolonged to 3-6 hours in hepatic impairment and >20 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Renal elimination: ~60% as penciclovir (active metabolite) and <10% as unchanged famciclovir; biliary/fecal: <5%; the remainder is metabolized to inactive compounds.
Category C
Category A/B
Antiviral
Antiviral
Famciclovir + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Famciclovir."